{"id":814926,"date":"2025-02-19T09:19:02","date_gmt":"2025-02-19T14:19:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/"},"modified":"2025-02-19T09:19:02","modified_gmt":"2025-02-19T14:19:02","slug":"gri-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/","title":{"rendered":"GRI Bio, Inc. Participates in the Virtual Investor \u201cTop 5 for \u201825\u201d On-Demand Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qXvcAQZfK-1j6uP2hZPOhddXHaVzv9GHYftjK2zU2QPmYma3EgLWDIJGSraTUYbkmH0C03f3KAwVVEqMI5I8ZN6E4BQTI-LfdPiyojA4zFoUE9-SglCcC1o7FyH9plyugYir93IzxJKF5YOG7pLtxg==\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <em><br \/>\n            <u>On-demand video webcast now available here<\/u><br \/>\n          <\/em><br \/>\n        <\/a><br \/>\n        <em><br \/>\n          <u>\u00a0<\/u><br \/>\n        <\/em>\n      <\/p>\n<p align=\"justify\">\n        <strong>LA JOLLA, CA, Feb.  19, 2025  (GLOBE NEWSWIRE) &#8212; <\/strong>GRI Bio, Inc. (NASDAQ: GRI) (\u201cGRI Bio\u201d or the \u201cCompany\u201d), a biotechnology company advancing an innovative pipeline of Natural Killer T (\u201cNKT\u201d) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced it participated in the Virtual Investor\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9xTAUELBHcQvCuXL02_DNbkydENVjat7Eg7qf2u53hT-Pj-zog3bjYk5ypaJpkqlfKJE40f78DhkBJQ-XhDLk68JkAjKwKRmLipqoNwlFd6LEmil1LjqJ4j5vM4LC46OUD-rbSuOVz4Kqh2ICuKPlQ==\" rel=\"nofollow\" target=\"_blank\"><u>&#8220;Top 5 for \u201825\u201d On-Demand Conference<\/u><\/a>.<\/p>\n<p align=\"justify\">As part of the event, Marc Hertz, Ph.D., Chief Executive Officer of GRI Bio, presented the top five reasons of why he believes the investment community and industry colleagues should pay attention to the Company in 2025.<\/p>\n<p align=\"justify\">The on-demand video webcast is now accessible for viewing <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=weJeEZivrBoXo9m1GgxA0AoOV2S7doGq-QVABn2s2rE_acpSnXYsJi2dFzKEFnqvcmgfcwtY0M8GzmSx8qOyxqLoFbSqZxfJCAj4uN1Maao=\" rel=\"nofollow\" target=\"_blank\"><u>here<\/u><\/a> and on the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hILNAy_1gciQ89EszA-7p6O5GYXFQzDftlAsA1zujYHWTT8434kXst977-MzMNhDUwWR-SCwbMftKtK1YQTxIw4kycMN3GzvV9xVTh50K50=\" rel=\"nofollow\" target=\"_blank\"><u>Event<\/u>s<\/a> page in the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JE3U39ET-Hz7878Frl3iEvFvar5gh8q4GBHJHM6HQ6XJtMeUCut4zw54nlQCtjD7U7yuPmds1E1ToqX7Vw1_jQ==\" rel=\"nofollow\" target=\"_blank\"><u>Investor<\/u>s<\/a> section of the Company\u2019s website <u>(<\/u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9s2L2v-cPrl8VcVCfmU5Sbd9XPwVelyeHrYuPRR1tOxlEInqGghwIoMuiK_Dj2BmQR3FKqBe52nkRBe5HtMcBA==\" rel=\"nofollow\" target=\"_blank\"><u>gribio.com<\/u><\/a><u>).<\/u><\/p>\n<p align=\"justify\">\n        <strong>About GRI Bio, Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio\u2019s therapies are designed to target the activity of NKT cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type 1 invariant (iNKT) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio\u2019s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 diverse NKT (dNKT) agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains \u201cforward-looking statements\u201d within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cseek,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d or the negative of these words or other similar expressions. These forward-looking statements are based on the Company\u2019s current beliefs and expectations. Forward-looking statements include, but are not limited to, statements regarding: the Company\u2019s expectations with respect to development and commercialization of the Company\u2019s product candidates, the timing of initiation or completion of clinical trials and availability of resulting data, the potential benefits and impact of the Company\u2019s clinical trials and product candidates and any implication that the data or results observed in preclinical trials or earlier studies or trials will be indicative of results of later studies or clinical trials, the Company\u2019s beliefs and expectations regarding potential shareholder value and future financial performance, the Company\u2019s beliefs about the timing and outcome of regulatory approvals and potential regulatory approval pathways, the Company\u2019s expected milestones for the first half of 2025, and the Company\u2019s beliefs and expectations regarding the sufficiency of its existing cash and cash equivalents to fund its planned operations, its ability to raise additional funds, which may not be available to the Company on acceptable terms or at all, and capital expenditure requirements. Actual results may differ from the forward-looking statements expressed by the Company in this press release and consequently, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including, without limitation: (1) the inability to maintain the listing of the Company\u2019s common stock on Nasdaq and to comply with applicable listing requirements; (2) changes in applicable laws or regulations; (3) the inability of the Company to raise financing in the future; (4) the success, cost and timing of the Company\u2019s product development activities; (5) the inability of the Company to obtain and maintain regulatory clearance or approval for its respective products, and any related restrictions and limitations of any cleared or approved product; (6) the inability of the Company to identify, in-license or acquire additional technology; (7) the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently developing; (8) the size and growth potential of the markets for the Company\u2019s products and services, and their respective ability to serve those markets, either alone or in partnership with others; (9) the failure to achieve any milestones or receive any milestone payments under any agreements; (10) inaccuracy in the Company\u2019s estimates regarding expenses, future revenue, capital requirements and needs for and the ability to obtain additional financing; (11) the Company\u2019s ability to protect and enforce its intellectual property portfolio, including any newly issued patents; and (12) other risks and uncertainties indicated from time to time in the Company\u2019s filings with the U.S. Securities and Exchange Commission (the \u201cSEC\u201d), including the risks and uncertainties described in the \u201cRisk Factors\u201d section of the Company\u2019s most recent Annual Report on Form 10-K filed with the SEC on March 28, 2024 and subsequently filed reports. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.<\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>JTC Team, LLC<br \/>Jenene Thomas<br \/>(908) 824-0775<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2SAlnvAQQTaKuzrB3SkTE7r_Lxf2aMxGhGkwfvh1A-Skk8bkil3SSqD3HJuN6nJHY7wzZzx2N9N-FyHFGFOEuA==\" rel=\"nofollow\" target=\"_blank\"><u>GRI@jtcir.com<\/u><\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MDcwOCM2NzU3MTI5IzUwMDA3NTQ4OA==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YjQ4Y2E5NzMtMzgzOC00NmJlLTk1NWItYWVjNzliMzY3MGI5LTUwMDA3NTQ4OA==\/tiny\/GRI-Bio-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>On-demand video webcast now available here \u00a0 LA JOLLA, CA, Feb. 19, 2025 (GLOBE NEWSWIRE) &#8212; GRI Bio, Inc. (NASDAQ: GRI) (\u201cGRI Bio\u201d or the \u201cCompany\u201d), a biotechnology company advancing an innovative pipeline of Natural Killer T (\u201cNKT\u201d) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced it participated in the Virtual Investor\u00a0&#8220;Top 5 for \u201825\u201d On-Demand Conference. As part of the event, Marc Hertz, Ph.D., Chief Executive Officer of GRI Bio, presented the top five reasons of why he believes the investment community and industry colleagues should pay attention to the Company in 2025. The on-demand video webcast is now accessible for viewing here and on the Events page in the Investors section of the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;GRI Bio, Inc. Participates in the Virtual Investor \u201cTop 5 for \u201825\u201d On-Demand Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-814926","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GRI Bio, Inc. Participates in the Virtual Investor \u201cTop 5 for \u201825\u201d On-Demand Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GRI Bio, Inc. Participates in the Virtual Investor \u201cTop 5 for \u201825\u201d On-Demand Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"On-demand video webcast now available here \u00a0 LA JOLLA, CA, Feb. 19, 2025 (GLOBE NEWSWIRE) &#8212; GRI Bio, Inc. (NASDAQ: GRI) (\u201cGRI Bio\u201d or the \u201cCompany\u201d), a biotechnology company advancing an innovative pipeline of Natural Killer T (\u201cNKT\u201d) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced it participated in the Virtual Investor\u00a0&#8220;Top 5 for \u201825\u201d On-Demand Conference. As part of the event, Marc Hertz, Ph.D., Chief Executive Officer of GRI Bio, presented the top five reasons of why he believes the investment community and industry colleagues should pay attention to the Company in 2025. The on-demand video webcast is now accessible for viewing here and on the Events page in the Investors section of the &hellip; Continue reading &quot;GRI Bio, Inc. Participates in the Virtual Investor \u201cTop 5 for \u201825\u201d On-Demand Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-19T14:19:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MDcwOCM2NzU3MTI5IzUwMDA3NTQ4OA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"GRI Bio, Inc. Participates in the Virtual Investor \u201cTop 5 for \u201825\u201d On-Demand Conference\",\"datePublished\":\"2025-02-19T14:19:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\\\/\"},\"wordCount\":907,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MDcwOCM2NzU3MTI5IzUwMDA3NTQ4OA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\\\/\",\"name\":\"GRI Bio, Inc. Participates in the Virtual Investor \u201cTop 5 for \u201825\u201d On-Demand Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MDcwOCM2NzU3MTI5IzUwMDA3NTQ4OA==\",\"datePublished\":\"2025-02-19T14:19:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MDcwOCM2NzU3MTI5IzUwMDA3NTQ4OA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MDcwOCM2NzU3MTI5IzUwMDA3NTQ4OA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gri-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GRI Bio, Inc. Participates in the Virtual Investor \u201cTop 5 for \u201825\u201d On-Demand Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GRI Bio, Inc. Participates in the Virtual Investor \u201cTop 5 for \u201825\u201d On-Demand Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/","og_locale":"en_US","og_type":"article","og_title":"GRI Bio, Inc. Participates in the Virtual Investor \u201cTop 5 for \u201825\u201d On-Demand Conference - Market Newsdesk","og_description":"On-demand video webcast now available here \u00a0 LA JOLLA, CA, Feb. 19, 2025 (GLOBE NEWSWIRE) &#8212; GRI Bio, Inc. (NASDAQ: GRI) (\u201cGRI Bio\u201d or the \u201cCompany\u201d), a biotechnology company advancing an innovative pipeline of Natural Killer T (\u201cNKT\u201d) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced it participated in the Virtual Investor\u00a0&#8220;Top 5 for \u201825\u201d On-Demand Conference. As part of the event, Marc Hertz, Ph.D., Chief Executive Officer of GRI Bio, presented the top five reasons of why he believes the investment community and industry colleagues should pay attention to the Company in 2025. The on-demand video webcast is now accessible for viewing here and on the Events page in the Investors section of the &hellip; Continue reading \"GRI Bio, Inc. Participates in the Virtual Investor \u201cTop 5 for \u201825\u201d On-Demand Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-19T14:19:02+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MDcwOCM2NzU3MTI5IzUwMDA3NTQ4OA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"GRI Bio, Inc. Participates in the Virtual Investor \u201cTop 5 for \u201825\u201d On-Demand Conference","datePublished":"2025-02-19T14:19:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/"},"wordCount":907,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MDcwOCM2NzU3MTI5IzUwMDA3NTQ4OA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/","name":"GRI Bio, Inc. Participates in the Virtual Investor \u201cTop 5 for \u201825\u201d On-Demand Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MDcwOCM2NzU3MTI5IzUwMDA3NTQ4OA==","datePublished":"2025-02-19T14:19:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MDcwOCM2NzU3MTI5IzUwMDA3NTQ4OA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MDcwOCM2NzU3MTI5IzUwMDA3NTQ4OA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gri-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"GRI Bio, Inc. Participates in the Virtual Investor \u201cTop 5 for \u201825\u201d On-Demand Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/814926","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=814926"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/814926\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=814926"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=814926"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=814926"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}